Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), intercepts the supply of blood which is indispensable for cancer to proliferate and metastasize to the whole body. We report a case of osteonecrosis of the jaw during chemotherapy using Bevacizumab in a 64-year-old woman with unresectable colorectal cancer. After surgical treatment for sigmoid colorectal cancer had been performed in the surgery department of another hospital, multiple lung and bone metastases were discovered. Therefore, she received Bevacizumab therapy combined with another chemotherapy. At the initial examination, there was exposed bone in the right mandibular lingual gingiva of the third molar region. This bone was isolated as a sequestrum and was easily removed. The surgical wound became completely covered with mucosal epithelia. There was no evidence of recurrence for 10 months after treatment.
We suspect that this osteonecrosis of the jaw was caused by the antiangiogenic property of Bevacizumab.
抄録全体を表示